

Claims

1. A stable pharmaceutical composition for oral administration comprising:

(i) a compound comprising a group of formula Y



wherein Z is H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, phenyl, phenyl substituted by OH, C_{1-6}alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C_{3-8}cycloalkyl, phenyl and phenyl substituted by OH, or CH_2-R_{4z} wherein R_{4z} is OH, acyloxy or a residue of formula (a)



wherein Z_1 is a direct bond or O, preferably O;
each of R_{5z} and R_{6z}, independently, is H, or C_{1-4}alkyl optionally substituted by 1, 2 or 3 halogen atoms;
R_{1z} is OH, acyloxy or a residue of formula (a); and each of R_{2z} and R_{3z} independently, is H, C_{1-4}alkyl or acyl; and

(i) 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol (FTY720) in free form, or a pharmaceutically acceptable salt thereof, and
(ii) one or more of the following excipients:
(a) Fillers selected from Mannitol, Xylitol, sorbitol, sucrose, Microcrystalline cellulose,, e.g. Avicel PH101, Dibasic calcium phosphate, Maltodextrin , gelatin
and/or

(a) a filler which is microcrystalline cellulose; and/or
(b)Binders selected from Povidone,
and/or

(c)Disintegrants selected from, Sodium carboxymethylstarch, a disintegrant which is pregelatinized starch, calcium silicate.

2. and/or

(d)Lubricants selected from Hydrogenated castor oil , Glycerol behenate , magnesium stearate, calcium stearate, zinc stearate, mineral oil, silicone fluid, sodium lauryl sulfate, L-leucine, sodium stearyl fumarate,

and/or

(e)Flow regulators selected from Talc

and/or

(f)Matrix formers selected from Methyl cellulose, Ethyl cellulose, Pullulan, Povidone

and/or

(g)Plastisizers selected from PEG 400, Dibutyl sebacate, Sorbitol

and/or

(h)Flavoring agents selected from Menthol, tutti fruti

and/or

(i)Sweeteners selected from Sucralose, Sodium saccharine

2. AThe composition of claim 1, wherein the excipients are selected from Sorbitol, Xylitol, dicalcium phosphate, microcrystalline cellulose, calcium silicate, talc, magnesium stearate and calcium stearate.

3. A composition of claim 1 or 2, wherein the composition comprises a binary blend consisting of a compound comprising a group of formula Y and one excipient.

4. A composition of any preceding claims, wherein the compound containing a group of formula Y is selected from 2-amino-2-[2-(4-octylphenyl)-ethyl]propane-1,3-diol (FTY720) in free form,.3-diolphosphate, or a pharmaceutically acceptable salt thereof, FTY720-phosphate, 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, and a prodrug thereof, preferably is FTY720and one of the excipients.

5. A3. The composition of any preceding claimsclaim 2, wherein the level of impuritiesimpurity is not more than 4.5wt5 wt % and/or no more than 2wt% for an individual impurity. has a percentage greater than 2 wt %.

6. A

4. The composition of any preceding claims for use as a pharmaceutical.

~~7. A composition according to any preceding claims,~~claim 1 in the form of a tablet~~,~~ or capsule.

5. The composition of claim 1, wherein the excipient is pregelatinized starch.

6. ~~8. The use of a composition of any preceding claims for the manufacture of a medicament for the treatment of organ or tissue transplant rejection, graft versus host disease, autoimmune diseases, inflammatory conditions, viral myocarditis, viral diseases caused by viral myocarditis or cancers.~~

~~9. A composition according to any one of claims 1 to 7, for use in the preparation of a medicament for the treatment of an autoimmune disease.~~

~~10. A composition according to any one of claims 1 to 7, for use in the preparation of a medicament for the treatment of multiple sclerosis.~~

~~11. A composition or an use according to any preceding claims wherein the compound of formula Y is selected from 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol (FTY720) in free form , a pharmaceutically acceptable salt thereof, FTY720-phosphate, 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, and a prodrug thereof.~~
The composition of claim 1, wherein the excipient is microcrystalline cellulose.